Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 tria𒁃ls of its COVID-19 vac🅷cine Covaxin, Suchitra Ella, joint managing director, Bharat Biotech International Ltd said on Thursday.
In a message posted on the company'ꦐs Twitter account, she thanked clinical trial sites, principal investigators and health workers for their support and trust in the "public-private partnership" vaccine discovery.
"My deep appreciation to all the vo🔯lunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of India's 1st fully indigenous COVID-19 vaccine," she sai🍸d referring to Covaxin.
Recently, Covaxin developed by Bharat Biotech was granted approval by India's drugs regulator for restricted emergency ꦓuse in the country.
The P🃏hase III human clinical trials of Covaxin began mid-November, targeted to be donꦐe in 26,000 volunteers across India.
The company ha♋d said it is the only Phase-3 efficacy study for a COVID-19 vaccine, and the largest efficacy trial (Phase-3) ever 𝓀conducted for any vaccine in India.
(With PTI inputs.)
